Showing 381-390 of 5345 results for "".
- Cutera Gives Back: Company Donates Tattoo Removal Laser to Gang Rehabilitation and Re-entry Programhttps://practicaldermatology.com/news/cutera-gives-back-company-donates-tattoo-removal-laser-to-gang-rehabilitation-and-re-entry-program/2460597/Cutera, Inc. is donating an enlighten tatoo removal laser along with clinical training and service to Homeboy Industries, a gang rehabilitation and re-entry program in Los Angeles. Homeboy Industries provides parenting classes, anger management and tattoo removal to support former
- Exclusive: Global Report Identifies Strategies for Improved Quality of Care in ADhttps://practicaldermatology.com/news/exclusive-global-report-identifies-strategies-for-improved-quality-of-care-in-ad/2460585/Gathering and synthesizing data from in-person visits from 32 care centers in 17 countries around the world, the “Improving Quality of Care in AD” report offers clear recommendations to improve care and help patients better manage atopic dermatitis.Commissioned and funded by Sano
- FDA Grants Priority Review for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe ADhttps://practicaldermatology.com/news/fda-grants-priority-review-for-pfizers-abrocitinib-an-oral-once-daily-jak1-inhibitor-for-patients-12-and-up-with-moderate-to-severe-ad/2460580/The U.S. Food and Drug Administration (FDA) has granted Priority Review designation to Pfizer’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in
- SOC, VisualDX, and NEJM Group Launch Webinar Series to Explore Issues in Skin Colorhttps://practicaldermatology.com/news/soc-visualdx-and-nejm-group-launch-webinar-series-to-explore-issues-in-skin-color/2460570/“The Impact of Skin Color and Ethnicity on Clinical Diagnosis and Research,” a new webinar series presented by the Skin of Color Society, NEJM Group, and VisualDx launches this month to call attention to health disparities and structural racism in medicine.
- Kerecis Scores DoD Grant to Develop, Test New Fish-skin Wound Treatment for Soldiershttps://practicaldermatology.com/news/kerecis-scores-dod-grant-to-develop-test-new-fish-skin-wound-treatment-for-soldiers/2460561/The U.S. Department of Defense (DoD) awarded a grant of almost $600,000 to Kerecis to test the company’s fish-skin technology to better stabilize battlefield wounds and provide a bacterial barrier for them during evacuation. The grant money will be disbursed to Kerecis over
- EB Research Partnership and EB Research Foundation Form Largest Global Organization Advancing EB Researchhttps://practicaldermatology.com/news/eb-research-partnership-and-eb-research-foundation-form-largest-global-organization-advancing-eb-research/2460559/EB Research Partnership (EBRP), based in New York, and EB Research Foundation (EBRF) of Australia are uniting to become the largest global organization focused on funding research to discover treatments and cures for Epidermolysis Bullosa (EB). As the two leading organiza
- Third RAD Conference Goes Virtual in Decemberhttps://practicaldermatology.com/news/third-rad-conference-goes-virtual-in-december/2460555/With a virtual format, the Third Revolutionizing Atopic Dermatitis (RAD) Conference is slated for December 13-14, 2020. Described by organizers as the first and only global, multidisciplinary conference dedicated to the discussion of evaluation and treatment options for atopi
- Brickell Biotech Initiates Phase 3 Trial of Sofpironium Bromide Gel for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-initiates-phase-3-trial-of-sofpironium-bromide-gel-for-hyperhidrosis/2460554/Brickell Biotech, Inc. has initiated its first pivotal US Phase 3 clinical study evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis (“Cardigan I Study”). “This continues to be an exciting time for Brickell, with initiati
- FemiClear for Genital Herpes Symptoms Launcheshttps://practicaldermatology.com/news/femiclear-for-genital-herpes-symptoms-launches/2460547/FemiClear brand has released new FemiClear for Genital Herpes Symptoms to relieve the symptoms of genital herpes outbreaks. This new product, backed by both an in vitroand in vivostudy, is now available at CVS stores nationwide. New
- Hoth Therapeutics’ HT-003 Inhibits Acne Gene TLR2https://practicaldermatology.com/news/hoth-therapeutics-ht-003-inhibits-acne-gene-tlr2/2460538/Hoth Therapeutics, Inc. completed testing on the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes. Initial data from the first phase of the research reports that toll-like receptor 2 (TLR2) is significantly